Angiopoietin-2 and Thrombospondin-2 Biomarker Detection for Acute Heart Failure

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current biomarker studies for acute heart failure face challenges due to modest specificity and incomplete validation, with existing methods relying on limited pathophysiologic pathways and requiring extensive clinical data and biosamples, which are costly and time-consuming to collect and validate.

Innovation Solution

A methodology combining electronic health record (EHR) data with an automated system for retrieving plasma from discarded clinical blood specimens, using a DNA aptamer-based proteomic platform to identify and validate candidate biomarkers such as angiopoietin-2 and thrombospondin-2 for diagnosing and treating acute heart failure.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If natriuretic peptides are used for diagnosing acute heart failure, then sensitivity is improved, but specificity deteriorates due to elevation by non-cardiac factors

Engineering Contradiction:

ImprovesensitivityVSAvoidspecificity

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The diagnostic approach segments the biomarker panel into multiple independent components (natriuretic peptides, angiopoietin-2, thrombospondin-2) and evaluates them separately and in combination. This allows the system to maintain high sensitivity through natriuretic peptides while compensating for their specificity limitations by adding complementary markers that respond differently to cardiac versus non-cardiac causes of dyspnea.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent merges multiple biomarker pathways into a unified diagnostic framework. By combining natriuretic peptides (cardiac stress markers) with angiopoietin-2 and thrombospondin-2 (vascular and fibrotic markers), the system creates a composite diagnostic signal that maintains sensitivity for acute heart failure while improving specificity by requiring concordance across multiple marker types.

Inventive Principle:

Principle #5Merging (Combining)

2Measurement precision

If traditional biomarker validation methods are used, then diagnostic accuracy is improved, but time and expense increase due to extensive data collection requirements

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidvalidation time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs preliminary actions by pre-characterizing the proteomic profile of discarded clinical specimens before they are needed for diagnostic validation. By establishing baseline proteomic patterns from these specimens in advance, the system eliminates the need for time-consuming prospective data collection during validation studies, thereby accelerating the diagnostic accuracy verification process.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The system uses discarded clinical specimens that would otherwise be wasted resources. These specimens self-provide the necessary biosamples for biomarker discovery and validation without requiring additional patient recruitment or specialized sample collection protocols, thereby reducing both time and expense while maintaining diagnostic accuracy.

Inventive Principle:

Principle #25Self-service

3Ease of manufacture

If discarded clinical specimens are used for biomarker discovery, then cost is reduced, but measurement precision may deteriorate due to sample degradation

Engineering Contradiction:

ImprovecostVSAvoidbiomarker detection accuracy

Core Design Contradiction:

Ease of manufactureVSMeasurement precision

Solution Approach 1:

The patent applies parameter changes by optimizing detection conditions for degraded specimens. By adjusting assay sensitivity thresholds, using proteomic profiling approaches that are less sensitive to degradation, and modifying sample processing parameters, the system maintains measurement precision even when working with discarded specimens that may have been stored under varying conditions.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The system replaces traditional mechanical sample handling and processing with automated proteomic platforms that use molecular recognition techniques. This substitution reduces the impact of sample degradation on measurement precision, as the automated systems can detect biomarkers through multiple conformational epitopes and are less susceptible to artifacts introduced by sample storage and handling variations.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances diagnostic accuracy for acute heart failure by improving specificity and reducing costs, allowing for the efficient identification of biomarkers from discarded specimens, thereby facilitating timely and effective treatment.

Implementation Method 1

using a DNA aptamer-based proteomic platform to identify and validate candidate biomarkers

Methodology Applied

Scientific EffectAptamer binding:

Data Source

PatentUS11079394B2Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure

Publication Date: 2021.08.03 BETH ISRAEL DEACONESS MEDICAL CENT INC

AI summary

Methods for detecting angiopoietin-2 (Angpt-2) and/or thrombospondin-2 (Tsp-2) in a sample involve obtaining or having obtained a blood or plasma sample from a subject; and detecting Angpt-2 and Tsp-2 in the sample. Detecting can involve performing an assay to determine whether the sample includes Angpt-2 and/or Tsp-2 or elevated levels of Angpt-2 and/or Tsp-2. Elevated levels are indicative of acute heart failure.